Effect of Patisiran on Stroke Volume in Hereditary Transthyretin ‐Mediated Amyloidosis: Insights from Pressure‐Volume Analysis of the APOLLO Study

ConclusionsPatisiran may delay progression of LV chamber dysfunction starting at 9 months of therapy. These data elucidate the mechanisms by which transthyretin reducing therapies modulate progression of cardiac disease and need to be confirmed in ongoing phase III trials.

Source: European Journal of Heart Failure - January 25, 2023 Category: Cardiology Authors: Hannah R. Rosenblum, Jan M. Griffin, Masatoshi Minamisawa, Narayana Prasad, John Vest, Matthew T. White, Scott D. Solomon, M.D. Daniel Burkhoff, Mathew S. Maurer Tags: Research Article Source Type: research